Evidence map›Paper›PMID 36845106›Full record

ArticleFrontiers in immunology2023

Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activation.

Caroline L Ashley, Brian P McSharry, Hamish E G McWilliam, Richard J Stanton, Ceri A Fielding, Rommel A Mathias, David P Fairlie, James McCluskey, Jose A Villadangos, Jamie Rossjohn and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. The immune response to human cytomegalovirus: impact of age, co-morbidities and the significance of anti-viral activity assessment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. The immune system in neurological diseases: What innate-like T cells have to say.The Journal of allergy and clinical immunology · 2024
    Review
  9. Review
  10. Article
  11. The Emerging Role of MAIT Cell Responses in Viral Infections.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Caroline L AshleyInfection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Brian P McSharryInfection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Hamish E G McWilliamDepartment of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Richard J StantonDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Ceri A FieldingDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Rommel A MathiasInfection and Immunity Program, Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
David P FairlieARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
James McCluskeyDepartment of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Jose A VilladangosDepartment of Microbiology and Immunology, The Peter Doherty Institute of Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Jamie RossjohnDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Allison AbendrothInfection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Barry SlobedmanInfection, Immunity and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, and the Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Cardiff University · GBThe University of Sydney · AUThe University of Melbourne · AUCharles Sturt University · AUMonash University · AUPeter Doherty Institute · AUThe University of Queensland · AU

Funding

Investigating the basis of MAIT cell antigen potencyR01AI148407 · NIAID · UNIVERSITY OF MELBOURNE · PI MCCLUSKEY, JAMES · 2020 to 2024
$2.7M
HCRW_ HS-20-30Medical Research Council MR/S00971X/1NIAID NIH HHS R01 AI148407Wellcome Trust
6 · The paper itself

Abstract

Introduction: The antigen presentation molecule MHC class I related protein-1 (MR1) is best characterized by its ability to present bacterially derived metabolites of vitamin B2 biosynthesis to mucosal-associated invariant T-cells (MAIT cells). Methods: Through in vitro human cytomegalovirus (HCMV) infection in the presence of MR1 ligand we investigate the modulation of MR1 expression. Using coimmunoprecipitation, mass spectrometry, expression by recombinant adenovirus and HCMV deletion mutants we investigate HCMV gpUS9 and its family members as potential regulators of MR1 expression. The functional consequences of MR1 modulation by HCMV infection are explored in coculture activation assays with either Jurkat cells engineered to express the MAIT cell TCR or primary MAIT cells. MR1 dependence in these activation assays is established by addition of MR1 neutralizing antibody and CRISPR/Cas-9 mediated MR1 knockout. Results: Here we demonstrate that HCMV infection efficiently suppresses MR1 surface expression and reduces total MR1 protein levels. Expression of the viral glycoprotein gpUS9 in isolation could reduce both cell surface and total MR1 levels, with analysis of a specific US9 HCMV deletion mutant suggesting that the virus can target MR1 using multiple mechanisms. Functional assays with primary MAIT cells demonstrated the ability of HCMV infection to inhibit bacterially driven, MR1-dependent activation using both neutralizing antibodies and engineered MR1 knockout cells. Discussion: This study identifies a strategy encoded by HCMV to disrupt the MR1:MAIT cell axis. This immune axis is less well characterized in the context of viral infection. HCMV encodes hundreds of proteins, some of which regulate the expression of antigen presentation molecules. However the ability of this virus to regulate the MR1:MAIT TCR axis has not been studied in detail.

Indexed as

Mucosal-Associated Invariant T CellsCytomegalovirusHistocompatibility Antigens Class IHumansMinor Histocompatibility AntigensReceptors, Antigen, T-CellHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanReceptors, Antigen, T-Cellherpesvirushuman cytomegalovirusimmune modulationMAIT cellsMHC class I related protein-1MR1mucosal-associated invariant T cells

Identifiers

PMID36845106
PMCPMC9950634
OpenAlexW4319938151

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.